Research Feeds

View All
Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson’s Disease Diagnosis of the menopause: NICE guidance and quality standards Causes of Death in End-Stage Kidney Disease: Comparison Between the United States Renal Data System and a Large Integrated Health Care System Factors affecting the absorption and excretion of lead in the rat Factors associated with age at menarche, menstrual knowledge, and hygiene practices among schoolgirls in Sharjah, UAE Cadmium transport in blood serum The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic Structured Exercise Benefits in Euthyroid Graves’ Disease: Improved Capacity, Fatigue, and Relapse Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease A Pilot Microbiota Study in Parkinson’s Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome Integrated Microbiome and Host Transcriptome Profiles Link Parkinson’s Disease to Blautia Genus: Evidence From Feces, Blood, and Brain Gut microbiota modulation: a narrative review on a novel strategy for prevention and alleviation of ovarian aging Long-term postmenopausal hormone therapy and endometrial cancer

The Positive Influence of Polyphenols Extracted From Pueraria lobata Root on the Gut Microbiota and Its Antioxidant Capability Original paper

Researched by:

  • Karen Pendergrass ID
    Karen Pendergrass

    User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

    Read More

March 18, 2025

Researched by:

  • Karen Pendergrass ID
    Karen Pendergrass

    User avatarKaren Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

    Read More

Last Updated: 2024-12-29

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.

Karen Pendergrass

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

What Was Studied?

This study examined the effects of a polyphenol-rich extract derived from Pueraria lobata (commonly known as kudzu root) on gut microbiota composition and antioxidant activity in both in vitro and in vivo models. Using antioxidant assays and high-throughput sequencing, the researchers investigated the extract’s ability to modulate oxidative stress and alter microbial populations in the gut.

Who Was Studied?

The in vivo experiments involved male C57BL/6 mice divided into control and experimental groups. The experimental group received a daily dose of 200 mg/kg of the P. lobata extract for 30 days, while the control group received water. Fecal samples were collected for gut microbiota analysis, and liver tissue was assessed for oxidative stress markers.

What Were the Most Important Findings?

The study demonstrated that the Pueraria lobata extract significantly improved antioxidant status and gut microbiota composition in mice. It enhanced key antioxidant enzyme activities, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), and reduced markers of oxidative stress like malondialdehyde (MDA). In terms of gut microbiota, the extract increased beneficial taxa (e.g., Lactobacillaceae, Bacteroidetes, and Rikenellaceae) while suppressing harmful families (e.g., Ruminococcaceae, Prevotellaceae, and Burkholderiaceae). These changes included favorable shifts in the Firmicutes-to-Bacteroidetes ratio, a crucial metric for metabolic and immune health. Functional analyses predicted alterations in cellular and neurological health pathways, underscoring the systemic effects of gut microbiota modulation by the extract.

Antioxidant Effects of P. lobata Extract

ParameterChange Observed
Superoxide dismutase (SOD)Increased by 25.7%
Glutathione peroxidase (GSH-Px)Increased by 21.6%
Total antioxidant capacity (T-AOC)Increased by 13.6%
Malondialdehyde (MDA)Reduced by 33.9%

Gut Microbiota Effects of P. lobata Extract

TaxaChange Observed
LactobacillaceaeIncreased 1.64-fold
BacteroidetesIncreased 3.96-fold
RikenellaceaeIncreased 2.02-fold
RuminococcaceaeDecreased by 66.8%
PrevotellaceaeDecreased by 23.3%
BurkholderiaceaeDecreased by 73.6%
ErysipelotrichaceaeMarkedly reduced (>90%)
AkkermansiaceaeMarkedly reduced (>90%)

What Are the Greatest Implications of This Study?

The findings suggest that Pueraria lobata extract could serve as a natural antioxidant and prebiotic, offering potential applications in managing oxidative stress-related conditions and gut dysbiosis. Its ability to selectively enhance beneficial microbes and suppress harmful ones makes it a promising candidate for developing functional foods or therapeutic interventions for chronic diseases such as metabolic syndrome, obesity, and neurodegenerative disorders. Additionally, the observed dual benefits of antioxidative and gut microbiota modulation highlight its multifaceted therapeutic potential.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.